Xconomy | San Diego - Business + Technology in the Exponential Economy

Sequenom May Spot Single-Gene Birth Defects, like Cystic Fibrosis, in a Sample of Mother’s Blood
Sequenom, Fueled by Blood Test for Down’s, Aims To Be “Google of Molecular Diagnostics”
Sequenom Starts 10,000-Patient Study To Diagnose Down Syndrome
Simple DNA Test Spots Deadly MRSA Bacteria; Adnavance Aims To Take It Mainstream
Vertex Co-Founder’s Hedge Fund RA Capital Makes Waves in Biotech Industry with Former Harvard Grad Student at Helm

Sequenom Licenses IP for Maternal Urine Tests

Sequenom (NASDAQ:SQNM), a San Diego-based provider of molecular diagnostics, reports that it has licensed exclusive rights from Monmouth Junction, NJ, diagnostics firm Xenomics (PINK:XNOM) to U.S. and European patents that cover the use of fetal DNA fragments found in a mother’s urine for prenatal diagnostics and research. As Luke discusses in this story, Sequenom is already deep into development of prenatal diagnostics that capture fetal DNA fragments from mothers’ blood samples.

Comments | Permalink |